Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Small Cell Lung Carcinoma 3Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Colorectal Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Peritoneal Neoplasms 1Osteosarcoma 1Liver, Cancer of, Primary Resectable 1Hepatocellular Carcinoma Resectable 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1Acute Toxic Effects 1

Interventions

Etoposide 79Carboplatin 67Cisplatin 58durvalumab 29Irinotecan 29Radiotherapy 27atezolizumab 23Topotecan 21anlotinib 19Nivolumab 15Drug Therapy 15Radiosurgery 14Gemcitabine 13apatinib 12Paclitaxel 12toripalimab 10Platinum 10Docetaxel 10tislelizumab 9Temozolomide 9PM 01183 8pembrolizumab 7olaparib 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Bevacizumab 7Albumin-Bound Paclitaxel 7irinotecan sucrosofate 6Counseling 6sintilimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Small Cell Lung Carcinoma × lobaplatin × Clear all
NCT03613597 2020-02-05

Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer

Guizhou Medical University

Phase 2 Unknown
118 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT03613753 2020-02-05

Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer

Guizhou Medical University

Phase 2 Unknown
72 enrolled
Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT03700359 2019-11-29

A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Unknown
60 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡